

September 2023



Our vision

Unlock the science to design breakthrough medicines in oncology.

Our objective

Is to provide medicinal chemistry solutions that will transform patient's lives. We rely on structure-based approaches against biological target to alleviate unmet medical need encountered in cancer resistance.

Our mission

transform lives of patients


Located in Lyon (Centre Léon Bérard), Kairos Discovery is a preclinical biopharmaceutical company, led by an expertise in medicinal chemistry to develop game-changing therapies in oncology.



Alexandre Bancet, PhD
Chief Executive Officer
Co-founder



Isabelle Krimm, PhD
Head of Research
Co-founder



David Neves
Head of Preclinical R&D
Co-founder



Alexandre Arnaud
R&D Engineer, Quality
Co-founder



Jean-Guillaume Lafay
Board of Director
CEO Mablink Biosciences



Stéphane Legastelois, PhD
Board of Director
President 33 Californie



Jean-Marie Grumel, MD
Board of Director
President HARA



Eglantine Rollet, PhD, MBA
Board of Director
Censor (TTO Pulsalys)



Prof. Jean-François Guichou, PhD
Scientific Advisory Board
CSO AGV Discovery



Prof. Jean-Yves Blay, MD, PhD
Scientific Advisory Board
CLB director



Prof. Marc Le Borgne, PharmaD, PhD
Scientific Advisory Board
Prof. of Medicinal Chemistry


Cancer resistance to kinase inhibitors remains a major challenge

- Kinase inhibitors & chemotherapies are initially effective but short-lived.
- Immunotherapies induce response in a minority of patients (only 20-40%).
- Combination of kinase inhibitors with immunotherapies hardly improves their efficacy.



A crucial need


A 38-year-old man with BRAF-mutant melanoma



Before initiation of vemurafenib (Roche)

After 15 weeks of therapy

After relapse (23 weeks of therapy)



Wagle, N., Emery, C. *et al.* Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. *J Clin Oncol.* **29**, 22 (2011).


Marshall, H.T. and Djamgoz, M.B.A. Immuno-Oncology: Emerging targets and combination therapies. *Front. Oncol.* **8**, 315 (2018).

Zhong, L., Li, Y., Xiong, L. *et al.* Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. *Sig Transduct Target Ther* **6**, 201 (2021).

Yang, Y., Li, S., Wang, Y. *et al.* Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. *Sig Transduct Target Ther* **7**, 329 (2022).

First program & competitive landscape

weaknesses of therapies inhibiting protein kinase CK2



CK2 inhibitors & representative patent examples



BMS 138
WO2011123493
ATP-competitive
Preclinical studies




silmitasertib
WO200802816
ATP-competitive
Clinical trials




CIGB300
WO2007098719
Substrate-competitive
Clinical trials

Today's problem




Non-selective profile
Adaptative resistance development
Cytostatic but not cytotoxic

With our first program, we are investigating next-generation **targeted cancer treatment**



Unique binding mode for a specific modulation




Cancer cell death


Inventing new possibilities

We use structure-based approaches to modulate functional activity of our target. Our resulting potent & selective compounds provide the means for us to develop new therapies for clinical evaluation in patients.

High selectivity



Proof of Concept in mice



KDX inhibitors are broadly active across a panel of cancer cell lines & selective for CK2.

Sustained **regression** with chemotherapies & TKIs combination.

Development plan

IP portofolio & clinical strategy

- **Patent 1 WO2022008475**

Signed exclusive licence agreement with Pulsalys

National phase entry in major territories

Indole derivatives and uses thereof treating a cancer

- **Patent 2 (Planned for 2024)**

« Back-up » compounds as agents against cancer

- **Patent 3 (Planned for 2024)**

Combination therapies with CK2 inhibitors to treat cancer



Addressing cancers with high unmet needs including large patient populations

With our first program targeting CK2, implicated in critical pathways, we have the potential to treat a broad range of hematologic malignancies & solid tumors.

First scenario : 2L monotherapy or combination with TKIs and/or with checkpoint inhibitors.



RCC



HCC



CRC




Glioblastoma,
Medulloblastoma



Others

Our focused path
from discovery to patients




B2B business model
with a drug portfolio

- Initial round of **€ 1.2 M** completed early 2023.
- Second round of **€ 4.0 M** planned for 2024.
- Exit plan based on lead program.
- Benchmark deal for M&A transaction : targeted oncology company with lead program in Phase 1/2 : **~ \$ 800 M.**

Our perspectives
CK2 selective inhibition

Advancing targeted novel oncology research platform : CK2 Bivalent Inhibition & CK2 signaling modifiers (e.g. CK2 PPI).



KAIROS DISCOVERY

Awards 



MÉTROPOLE

GRAND LYON

Contact 

Alexandre Bancet

a.bancet@kairos-discovery.com

+336 20 57 68 18